Taxonomy of the Houbara Bustard Chlamydotis undulata subspecies considered on the basis of sexual display and genetic divergence

The Houbara Bustard Chlamydotis undulata is a polytypic species with three subspecies classified according size, colour and distribution: C. u. undulata, C. u. fuertaventurae and C. u. macqueenii. A comparative study of the male display behaviour of these three subspecies has shown similarities between C. u. undulata and C. u. fuertaventurae , whereas appreciable differences exist in the visual and auditory aspects of the display between C. u. undulata and C. u. macqueenii. These observations make the current taxonomy of Houbara Bustard questionable, particularly in view of the major importance of the sexual display in bird speciation processes. Furthermore, DNA analysis of the cytochrome b gene indicates the existence of a significant differentiation between the C. u. undulata and C. u. macqueenii populations. These findings indicate the need for a revision of the taxonomy of genus Chlamydotis which should separate the macqueenii and undulata populations at species rank. Until further investigations are completed, C. u. fuertaventurae should be kept as a subspecies of undulata since the courtship display is alike in both populations.     

Addressing cancer immunotherapy research in Iran: adoptive cell therapy on the horizon

Recent advances in immunotherapeutic modalities have profoundly changed the prospect of cancer treatment. These modalities mainly focus on modulating the immune response toward tumor cells by using monoclonal antibodies, cancer vaccines, adoptive cell transfer or combination of these methods. In the last few years, Iranian scientists have conducted several projects in these arenas. Here, we provide an overview of these studies and analyze the quality and trend of publications in each sub-specialty of the field. In addition, the contribution of different universities and scientific institutes is assessed. This study may benefit scientific community and policymakers to plan future cancer immunotherapies in Iran and other countries.